Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Deferred Revenue (2019 - 2026)

C4 Therapeutics has reported Current Deferred Revenue over the past 8 years, most recently at $25.6 million for Q1 2026.

  • For Q1 2026, Current Deferred Revenue fell 45.26% year-over-year to $25.6 million; the TTM value through Mar 2026 reached $25.6 million, down 45.26%, while the annual FY2025 figure was $28.3 million, 51.42% up from the prior year.
  • Current Deferred Revenue for Q1 2026 was $25.6 million at C4 Therapeutics, down from $28.3 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $49.4 million in Q3 2024 and troughed at $8.4 million in Q3 2023.
  • A 5-year average of $29.1 million and a median of $30.8 million in 2023 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: crashed 75.86% in 2023 and later skyrocketed 486.62% in 2024.
  • Year by year, Current Deferred Revenue stood at $33.5 million in 2022, then tumbled by 53.84% to $15.5 million in 2023, then rose by 20.95% to $18.7 million in 2024, then surged by 51.42% to $28.3 million in 2025, then decreased by 9.78% to $25.6 million in 2026.
  • Business Quant data shows Current Deferred Revenue for CCCC at $25.6 million in Q1 2026, $28.3 million in Q4 2025, and $17.1 million in Q3 2025.